Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells

Misawa, Tomoka; Toyoshima, Masafumi; Kitatani, Kazuyuki; Ishibashi, Masayoshi; Hasegawa-Minato, Junko; Shigeta, Shogo; Yaegashi, Nobuo

doi:10.1016/j.ctarc.2021.100364

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 119 Recently, tyrosine kinase with immunoglobulin-like and EGF-like domains (TIE-1) have been explored for their role in ovarian cancer chemoresistance, where the authors demonstrated that EVs associated with TIE-1 led to cisplatin resistance in recipient cells by decreasing the DNA damage effects of cisplatin. 120 It is also reported that, when treated with cisplatin, ovarian cancer cells released EVs, which promoted tumor cell invasion and resistance to therapy particularly when bystander cells, which are free from cellular stress, uptake the cancer cell released EVs. 121 Emerging evidence of the role of EVs in ovarian cancer chemoresistance highlights the importance of further investigation of EV-mediated immune evasion, metastasis, and chemoresistance.…”

Section: Introductionmentioning

confidence: 98%

Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies

McAlarnen

Gupta

Singh

et al. 2022

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies

McAlarnen

Gupta

Singh

et al. 2022

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

“… 14 . Additionally, TIE1 significantly influences the resistance of ovarian cancer cells to platinum therapy 15 . However, the exact role of TIE1 in GC and its potential regulatory mechanisms remain uncertain.…”

Section: Introductionmentioning

confidence: 99%

Identification of the Expression of TIE1 and Its Mediated Immunosuppression in Gastric Cancer

Gong,

Zheng,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Background: Recently, various evidence has confirmed that Tyrosine Kinase with Immunoglobulin-like and EGF-like domains 1 (TIE1) promotes tumor growth in many cancers. However, the precise mechanism underlying TIE1's involvement in Gastric Cancer (GC) remains elusive. This research aimed to investigate the biological function of TIE1 in regulating GC progression. Methods: The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), GEPIA2.0, Sangerbox3.0 and TIMER databases were used to analyze the TIE1 expression. Immunohistochemistry (IHC) was used to demonstrate the expression of TIE1. TCGA, GEPIA2.0 and Kaplan-Meier were utilized for survival analysis and to explore the association of TIE1 with clinicopathological features. Protein-Protein Interaction (PPI) networks were constructed using Cytoscape. The potential molecular mechanism of TIE1 was investigated by Gene Ontology (GO), Kyoto Encyclopedia of Gene Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA). We studied the relationships between TIE1 and mutations, immune checkpoints (ICs), tumor mutational burden (TMB), as well as microsatellite instability (MSI) to explore the underlying mechanism of immunity in GC. Results: Compared with normal tissue, TIE1 was significantly overexpressed in GC tissues (p = 0.0072) and was associated with poor survival (P < 0.05). According to GO and KEGG enrichment analyses, TIE1 was enriched in signal pathways related to the occurrence, invasion, and migration of malignant tumors (i.e., PI3K-Akt signaling pathway, Calcium signaling pathway, etc.). Immune infiltration analysis suggested that TIE1 is positively correlated with macrophages M2 and negatively correlated with Mast cells, naive B cells and Follicular helper T cells (TFH), which may be a contributing factor to tumor progression. Furthermore, the research on the tumor microenvironment (TME) and tumor purity also proved that TIE1 may be an oncogene. Mutation analysis showed that the high expression group of TIE1 had a higher frequency of mutations in TP53 and ARID1, while the TMB score was lower. Conclusion: TIE1 might be an oncogene via regulating dysregulated immune infiltration to cause immunosuppression in GC and could be identified as a biomarker for prognosis and a therapeutic target for GC.

show abstract

Cervical cancer cell-derived Tie1 expression via PI3K/AKT signaling pathway promotes tumor progression

Wei,

Yu,

Zhao

et al. 2024

Experimental Cell Research

View full text Add to dashboard Cite

Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells

Cited by 4 publications

References 30 publications

Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies

Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies

Identification of the Expression of TIE1 and Its Mediated Immunosuppression in Gastric Cancer

Cervical cancer cell-derived Tie1 expression via PI3K/AKT signaling pathway promotes tumor progression

Contact Info

Product

Resources

About